Pharma News: Patent Cliffs, M&A Moves, and Regulatory Shifts

The pharmaceutical industry is under scrutiny as the FDA and FTC monitor patent expirations and anticompetitive practices. Prestige Consumer Healthcare's acquisition and FDA's new testing guidelines highlight shifts in drug development. Meanwhile, meningitis outbreaks and policy changes in vaccine administration showcase ongoing health challenges.

The pharmaceutical sector faces significant developments, with U.S. regulatory bodies keeping a close watch on patent cliffs and market competition. The Federal Trade Commission is actively monitoring potential anticompetitive practices as numerous blockbuster drug patents near expiration, aiming to protect consumer interests against soaring prices.

In another major industry move, Prestige Consumer Healthcare has announced its acquisition of the Breathe Right brand for $1.05 billion, marking a strategic expansion. Meanwhile, the U.S. Food and Drug Administration has issued guidance encouraging alternatives to animal testing in drug trials, pushing for cutting-edge methods like computer simulations.

Across the Atlantic, health officials in the UK are battling a meningitis outbreak as they roll out vaccines following deaths in southeast England. Concurrently, political and regulatory changes in the U.S. reveal fluctuating stances on drug pricing and child vaccination policies, showing the complex landscape of healthcare governance globally.

(With inputs from agencies.)